Identification of a -Specific Modifier Locus at 6p24 Related to Breast Cancer Risk

English version České info

Common genetic variants contribute to the observed variation in breast cancer risk for BRCA2 mutation carriers; those known to date have all been found through population-based genome-wide association studies (GWAS). To comprehensively identify breast cancer risk modifying loci for BRCA2 mutation carriers, we conducted a deep replication of an ongoing GWAS discovery study. Using the ranked P-values of the breast cancer associations with the imputed genotype of 1.4 M SNPs, 19,029 SNPs were selected and designed for inclusion on a custom Illumina array that included a total of 211,155 SNPs as part of a multi-consortial project. DNA samples from 3,881 breast cancer affected and 4,330 unaffected BRCA2 mutation carriers from 47 studies belonging to the Consortium of Investigators of Modifiers of BRCA1/2 were genotyped and available for analysis. We replicated previously reported breast cancer susceptibility alleles in these BRCA2 mutation carriers and for several regions (including FGFR2, MAP3K1, CDKN2A/B, and PTHLH) identified SNPs that have stronger evidence of association than those previously published. We also identified a novel susceptibility allele at 6p24 that was inversely associated with risk in BRCA2 mutation carriers (rs9348512; per allele HR = 0.85, 95% CI 0.80–0.90, P = 3.9×10⁻⁸). This SNP was not associated with breast cancer risk either in the general population or in BRCA1 mutation carriers. The locus lies within a region containing TFAP2A, which encodes a transcriptional activation protein that interacts with several tumor suppressor genes. This report identifies the first breast cancer risk locus specific to a BRCA2 mutation background. This comprehensive update of novel and previously reported breast cancer susceptibility loci contributes to the establishment of a panel of SNPs that modify breast cancer risk in BRCA2 mutation carriers. This panel may have clinical utility for women with BRCA2 mutations weighing options for medical prevention of breast cancer.

Vyšlo v časopise: Identification of a -Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genet 9(3): e32767. doi:10.1371/journal.pgen.1003173
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003173

Souhrn

Zdroje

1. AntoniouAC, CunninghamAP, PetoJ, EvansDG, LallooF, et al. (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98: 1457–1466.

2. GaudetMM, KirchhoffT, GreenT, VijaiJ, KornJM, et al. (2010) Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet 6: e1001183 doi:10.1371/journal.pgen.1001183.

3. TurnbullC, AhmedS, MorrisonJ, PernetD, RenwickA, et al. (2010) Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 42: 504–507.

4. LindstromS, VachonCM, LiJ, VargheseJ, ThompsonD, et al. (2011) Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. Nat Genet 43: 185–187.

5. CouchFJ, GaudetMM, AntoniouAC, RamusSJ, KuchenbaeckerKB, et al. (2012) Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 21: 645–657.

6. Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst 98: 1382–1396.

7. GaytherSA, SongH, RamusSJ, KjaerSK, WhittemoreAS, et al. (2007) Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res 67: 3027–3035.

8. Kote-JaraiZ, EastonDF, StanfordJL, OstranderEA, SchleutkerJ, et al. (2008) Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev 17: 2052–2061.

9. Kermani BG (2008) Artificial intelligence and global normalization methods for genotype.

10. RobertsonA, HillWG (1984) Deviations from Hardy-Weinberg proportions: sampling variances and use in estimation of inbreeding coefficients. Genetics 107: 703–718.

11. A map of human genome variation from population-scale sequencing. Nature 467: 1061–1073.

12. HowieBN, DonnellyP, MarchiniJ (2009) A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 5: e1000529 doi:10.1371/journal.pgen.1000529.

13. CouchFJ, WangX, McGuffogL, LeeA, OlswoldC, et al. (2012) Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. Nat Genet under review

14. MichailidouK, HallP, Gonzalez-NeiraA, GhoussainiM, DennisJ, et al. (2012) Large-scale genotyping identifies 38 new breast cancer susceptibility loci. Nat Genet under review

15. Barnes D, Lee A, Embrace, Easton D, Antoniou AC (2012) Evaluation of association methods for analyzing modifiers of disease risk in carriers of high-risk mutations. Genet Epidemiol in press.

16. AntoniouAC, GoldgarDE, AndrieuN, Chang-ClaudeJ, BrohetR, et al. (2005) A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol 29: 1–11.

17. AntoniouAC, SinilnikovaOM, SimardJ, LeoneM, DumontM, et al. (2007) RAD51 135G–>C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 81: 1186–1200.

18. AntoniouAC, WangX, FredericksenZS, McGuffogL, TarrellR, et al. (2010) A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet 42: 885–892.

19. MulliganAC, CouchFJ, BarrowdaleD, DomchekSM, EcclesD, et al. (2011) Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res 13: R110.

20. AulchenkoYS, RipkeS, IsaacsA, van DuijnCM (2007) GenABEL: an R library for genome-wide association analysis. Bioinformatics 23: 1294–1296.

21. LangeK, WeeksD, BoehnkeM (1988) Programs for Pedigree Analysis: MENDEL, FISHER, and dGENE. Genet Epidemiol 5: 471–472.

22. LiuJZ, McRaeAF, NyholtDR, MedlandSE, WrayNR, et al. (2010) A versatile gene-based test for genome-wide association studies. Am J Hum Genet 87: 139–145.

23. AshburnerM, BallCA, BlakeJA, BotsteinD, ButlerH, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25–29.

24. AntoniouAC, BeesleyJ, McGuffogL, SinilnikovaOM, HealeyS, et al. (2010) Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res 70: 9742–9754.

25. AntoniouAC, KuchenbaeckerKB, SoucyP, BeesleyJ, ChenX, et al. (2012) Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res 14: R33.

26. FriedrichsN, JagerR, PaggenE, RudlowskiC, Merkelbach-BruseS, et al. (2005) Distinct spatial expression patterns of AP-2alpha and AP-2gamma in non-neoplastic human breast and breast cancer. Mod Pathol 18: 431–438.

27. GeeJM, RobertsonJF, EllisIO, NicholsonRI, HurstHC (1999) Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. J Pathol 189: 514–520.

28. GaubatzS, ImhofA, DoschR, WernerO, MitchellP, et al. (1995) Transcriptional activation by Myc is under negative control by the transcription factor AP-2. EMBO J 14: 1508–1519.

29. McPhersonLA, LoktevAV, WeigelRJ (2002) Tumor suppressor activity of AP2alpha mediated through a direct interaction with p53. J Biol Chem 277: 45028–45033.

30. ZhangH, MengF, LiuG, ZhangB, ZhuJ, et al. (2011) Forkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis. Cancer Res 71: 1292–1301.

31. ZhangH, MengF, WuS, KreikeB, SethiS, et al. (2011) Engagement of I-branching {beta}-1, 6-N-acetylglucosaminyltransferase 2 in breast cancer metastasis and TGF-{beta} signaling. Cancer Res 71: 4846–4856.

32. AntoniouAC, SpurdleAB, SinilnikovaOM, HealeyS, PooleyKA, et al. (2008) Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 82: 937–948.

33. AntoniouAC, SinilnikovaOM, McGuffogL, HealeyS, NevanlinnaH, et al. (2009) Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 18: 4442–4456.

34. AntoniouAC, KuchenbaeckerKB, SoucyP, BeesleyJ, ChenX, et al. (2012) Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res 14: R33.

35. AntoniouAC, KartsonakiC, SinilnikovaOM, SoucyP, McGuffogL, et al. (2011) Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 20: 3304–3321.